Suppr超能文献

转移性结肠癌的全身治疗：新前沿

Systemic Therapy for Metastatic Colon Cancer: New Frontiers.

作者信息

Pumpalova Yoanna S

机构信息

Division of Hematology and Oncology, Department of Internal Medicine, Columbia University Irving Medical Center, New York, New York.

出版信息

Clin Colon Rectal Surg. 2024 Jun 25;38(3):229-236. doi: 10.1055/s-0044-1787826. eCollection 2025 May.

DOI:10.1055/s-0044-1787826
PMID:40291998
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12020547/
Abstract

We have made steady gains in improving overall survival in patients with metastatic, unresectable, colon cancer in the last 5 to 10 years. The backbone of systemic treatment for most patients remains combination chemotherapy, but the field is becoming increasingly biomarker driven, with exciting new targeted therapies on the horizon. This review is organized in sections corresponding to currently relevant biomarkers in colon cancer and will summarize first-, second-, and third-line standard of care for metastatic, unresectable, colon cancer. The last section is intended to introduce the reader to promising agents and novel therapeutic strategies currently under investigation.

摘要

在过去5到10年中，我们在改善转移性、不可切除结肠癌患者的总生存率方面取得了稳步进展。对大多数患者来说，全身治疗的主要方法仍然是联合化疗，但该领域正越来越多地由生物标志物驱动，有令人兴奋的新靶向疗法即将出现。本综述按与结肠癌当前相关的生物标志物进行章节编排，将总结转移性、不可切除结肠癌的一线、二线和三线标准治疗方案。最后一部分旨在向读者介绍目前正在研究的有前景的药物和新型治疗策略。

相似文献

1
Systemic Therapy for Metastatic Colon Cancer: New Frontiers.
Clin Colon Rectal Surg. 2024 Jun 25;38(3):229-236. doi: 10.1055/s-0044-1787826. eCollection 2025 May.
2
Systemic treatments for metastatic cutaneous melanoma.
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
3
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
4
Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.
Cochrane Database Syst Rev. 2017 Jun 27;6(6):CD007047. doi: 10.1002/14651858.CD007047.pub2.
5
A systematic overview of chemotherapy effects in colorectal cancer.
Acta Oncol. 2001;40(2-3):282-308. doi: 10.1080/02841860151116367.
6
Chemotherapy for advanced gastric cancer.
Cochrane Database Syst Rev. 2017 Aug 29;8(8):CD004064. doi: 10.1002/14651858.CD004064.pub4.
7
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
8
Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.
Cochrane Database Syst Rev. 2021 Nov 16;11(11):CD012775. doi: 10.1002/14651858.CD012775.pub2.
9
A systematic overview of chemotherapy effects in breast cancer.
Acta Oncol. 2001;40(2-3):253-81. doi: 10.1080/02841860151116349.
10
Systemic therapy for treating locoregional recurrence in women with breast cancer.
Cochrane Database Syst Rev. 2001;2001(4):CD002195. doi: 10.1002/14651858.CD002195.

本文引用的文献

1
Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study.
J Clin Oncol. 2024 Aug 20;42(24):2918-2927. doi: 10.1200/JCO.23.02736. Epub 2024 Jun 4.
2
Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort.
Nat Commun. 2024 Feb 20;15(1):1533. doi: 10.1038/s41467-024-45960-2.
3
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated G12C.
N Engl J Med. 2023 Dec 7;389(23):2125-2139. doi: 10.1056/NEJMoa2308795. Epub 2023 Oct 22.
4
Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer: A Systematic Literature Review and Meta-Analysis of Clinical Outcomes.
Oncologist. 2023 Oct 3;28(10):885-893. doi: 10.1093/oncolo/oyad200.
5
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study.
Lancet. 2023 Jul 1;402(10395):41-53. doi: 10.1016/S0140-6736(23)00772-9. Epub 2023 Jun 15.
6
Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer.
Nat Commun. 2023 Jun 7;14(1):3332. doi: 10.1038/s41467-023-38032-4.
7
The Therapeutic Landscape for -Mutated Colorectal Cancers.
Cancers (Basel). 2023 Apr 19;15(8):2375. doi: 10.3390/cancers15082375.
8
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study.
Lancet Oncol. 2023 May;24(5):496-508. doi: 10.1016/S1470-2045(23)00150-X.
9
Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer.
N Engl J Med. 2023 May 4;388(18):1657-1667. doi: 10.1056/NEJMoa2214963.
10
Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study.
EClinicalMedicine. 2023 Apr 6;58:101917. doi: 10.1016/j.eclinm.2023.101917. eCollection 2023 Apr.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验